News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Valeant Pharmaceuticals International (VRX) Announces 2014 Annual Meeting Results


5/21/2014 9:09:09 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

LAVAL, Quebec, May 21, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced the election of ten directors nominated at its 2014 annual meeting of shareholders today. The detailed results of the vote for the election of directors are set out below:

Name


For


Withheld


Broker Non-Votes










Ronald H. Farmer


251,288,239


908,255


21,179,009


Colleen A. Goggins


251,712,817


483,677


21,179,009


Robert A. Ingram


249,639,221


2,557,273


21,179,009


Anders Lonner


251,650,643


545,851


21,179,009


Theo Melas-Kyriazi


251,423,599


772,895


21,179,009


J. Michael Pearson


246,575,385


5,621,109


21,179,009


Robert N. Power


250,186,656


2,009,838


21,179,009


Norma A. Provencio


251,604,073


592,421


21,179,009


Howard B. Schiller


238,521,290


13,675,204


21,179,009


Katharine B. Stevenson


250,315,363


1,881,131


21,179,009


At the annual meeting, shareholders also approved the non-binding advisory vote on named executive officer compensation as disclosed in the proxy statement; appointed PricewaterhouseCoopers LLP (United States) as the Company's independent registered public accounting firm until the close of the Company's 2015 annual meeting of shareholders; and approved the 2014 Omnibus Incentive Plan and the ratification and approval of the grants of 320,033 share units and 180,000 options which were made subject to the shareholder approval of the 2014 Plan.

The final vote tabulation on all matters voted on at today's meeting will be reported to the U.S. Securities and Exchange Commission on a current report on Form 8-K and such report will be made available on the Company's web site, www.valeant.com.

About Valeant Pharmaceuticals International, Inc.

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, eye health, neurology and branded generics. More information about Valeant can be found at www.valeant.com.

Contact Information:
Laurie W. Little
949-461-6002
laurie.little@valeant.com

Valeant Pharmaceuticals International, Inc.

Logo - http://photos.prnewswire.com/prnh/20101025/LA87217LOGO

SOURCE Valeant Pharmaceuticals International, Inc.



Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES